148 related articles for article (PubMed ID: 18406001)
41. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
[TBL] [Abstract][Full Text] [Related]
42. [Parameters related to fibrinolysis and their meanings].
Urano T; Suzuki Y
Rinsho Byori; 2011 Jul; 59(7):703-8. PubMed ID: 21874797
[TBL] [Abstract][Full Text] [Related]
43. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
44. A new euglobulin clot lysis assay for global fibrinolysis.
Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
[TBL] [Abstract][Full Text] [Related]
45. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
46. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
47. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
48. [Changes in hemostasis and fibrinolysis in gestational diabetes].
Kvasnicka J; Bendl J; Zivný J; Umlaufová A; Maslowská H
Cas Lek Cesk; 1996 Feb; 135(4):106-10. PubMed ID: 8625379
[TBL] [Abstract][Full Text] [Related]
49. [Value of coagulation function and fibrinolytic system assessment in patients with gestational diabetes mellitus].
Liu BY; Jian YL; Zhong M; Yu YH; Wang Q; Zhang J
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):35-7. PubMed ID: 17259140
[TBL] [Abstract][Full Text] [Related]
50. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Van Thiel DH; George M; Fareed J
Thromb Haemost; 2001 Apr; 85(4):667-70. PubMed ID: 11341503
[TBL] [Abstract][Full Text] [Related]
51. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
52. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
53. Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.
Sayilir A; Beyazit Y; Yesil Y; Albayrak M; Ekiz F; Celik T; Suvak B; Torun S; Ibiş M
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):498-504. PubMed ID: 22230218
[TBL] [Abstract][Full Text] [Related]
54. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
Wada H; Nobori T; Watanabe R; Shiku H; Sakuragawa N
Turk J Haematol; 2002 Jun; 19(2):235-7. PubMed ID: 27264764
[TBL] [Abstract][Full Text] [Related]
55. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB; Koschinsky ML
Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
[TBL] [Abstract][Full Text] [Related]
56. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
[TBL] [Abstract][Full Text] [Related]
57. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
58. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels.
Ozkan G; Ulusoy S; Sönmez M; Karahan SC; Menteşe A; Kaynar K; Bektaş O
Clin Exp Hypertens; 2013; 35(2):134-40. PubMed ID: 22799880
[TBL] [Abstract][Full Text] [Related]
59. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy.
Mousa HA; Downey C; Alfirevic Z; Toh CH
Thromb Haemost; 2004 Nov; 92(5):1025-31. PubMed ID: 15543330
[TBL] [Abstract][Full Text] [Related]
60. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
Nielsen VG; Ellis TC
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
